


Journal Pre-proof

Sars-Cov-2: Underestimated damage to nervous system

Lingyan Zhou, Meng Zhang, Jing Gao, Jing Wang



PII: S1477-8939(20)30110-1

DOI: <https://doi.org/10.1016/j.tmaid.2020.101642>

Reference: TMAID 101642

To appear in: *Travel Medicine and Infectious Disease*

Received Date: 9 March 2020

Revised Date: 18 March 2020

Accepted Date: 20 March 2020

Please cite this article as: Zhou L, Zhang M, Gao J, Wang J, Sars-Cov-2: Underestimated damage to nervous system, *Travel Medicine and Infectious Disease* (2020), doi: <https://doi.org/10.1016/j.tmaid.2020.101642>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.

Sars-Cov-2: underestimated damage to nervous system

Lingyan Zhou^{1*}, Meng Zhang^{1*}, Jing Wang², Jing Gao¹

¹Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao266000, China

²Department of Rheumatology, The Affiliated Hospital of Qingdao University, Qingdao266000, China

Corresponding Author: Jing Gao, E-mail: sunshinezlyjg@163.com, China.

*These authors contributed to this work equally and should be regarded as co-first authors.

Dear Editor,

Coronaviruses (CoVs) are large enveloped positive-stranded RNA viruses, which generally induce enteric and respiratory diseases in animals and humans^[1]. Novel coronavirus pneumonia (NCP, also called COVID-19) emerged in December 2019 in Wuhan, China^[1]. This novel CoV(SARS-CoV-2) has caused a national outbreak of severe pneumonia in China, and rapidly spreads around the world.

On March 4, gene sequencing confirmed the presence of SARS-CoV-2 in the cerebrospinal fluid of a 56-year-old patient with NCP in Beijing Ditan Hospital. The patient was diagnosed with viral encephalitis, and the patient's central nervous system was attacked by SARS-CoV-2. This indicates that SARS-CoV-2 can directly invade the nervous system of patients, instead of injuring the nervous system through the immune response to SARS-CoV-2. This is the first evidence that SARS-CoV-2 has directly invaded the nervous system.

Genomic analysis shows that SARS-CoV-2 is in the same Betacoronavirus clade as

MERS-CoV and SARS-CoV, and shares highly homological sequence with SARS-CoV^[1].

The public evidence shows that COVID-19 shares similar pathogenesis with the pneumonia induced by SARS-CoV or MERS-CoV^[2]. Moreover, the entry of SARS-CoV-2 into human host cells has been identified to use the same receptor as SARS-CoV^[1]. Previous studies have shown that SARS-CoV and MERS-CoV possess neuroinvasive properties, which can be detected in human brains. CoVs may enter the CNS through two distinct routes: hematogenous dissemination or neuronal retrograde dissemination. I think that the way of neuronal retrograde dissemination is more worrying.

HCoV-OC43 RNA, a kind of human coronaviruses, could be detected for at least a year in the CNS of infected mice that survived the virus-induced acute encephalitis^[3]. Therefore, an apparently innocuous human respiratory pathogen may persist in the human CNS as a component of the brain, like herpes simplex virus (HSV) in a large proportion of the population. If SARS-CoV-2 exists for a long time, like HSV, and it will recur again in predisposed individuals.

In addition, the presence of HCoV-229E and HCoV-OC43 was detected in various neurological diseases in humans, including multiple sclerosis (MS)^[4]. Multiple sclerosis truly represents a human neurological disease where an infectious agent or agents may play a triggering role, with viruses the most likely culprit in genetically predisposed individuals^[5]. If the SARS-CoV-2 is latent in CNS for a long time, will the cured patients reappear with neurological diseases because of the latentness of the SARS-CoV-2, which is a doubt for the late neurological complications of the cured patients. If the SARS-CoV-2 is latent in the nervous system for a long period of time, will the cured patients reappear with neurological

diseases? This is a question for the cured patients. It is worthy of our further discovery and exploration. In addition, we should also be aware of this problem in further clinical work, strengthen the alertness of clinicians, and jointly solve this problem.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

- [1] Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis[J]. Travel medicine and infectious disease, 2020: 101606.
- [2] Song Z, Xu Y, Bao L, et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight[J]. Viruses, 2019, 11(1).
- [3] Jacomy H, Fragoso G, Almazan G, et al. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice[J]. Virology, 2006, 349(2): 335-46.
- [4] Arbour N, Day R, Newcombe J, et al. Neuroinvasion by human respiratory coronaviruses[J]. Journal of virology, 2000, 74(19): 8913-21.
- [5] Kurtzke J F. Epidemiologic evidence for multiple sclerosis as an infection[J]. Clinical microbiology reviews, 1993, 6(4): 382-427.



ELSEVIER

Travel Medicine and Infectious Disease

Conflict of Interest Policy

Manuscript number (if applicable):

Article Title: **Sars-Cov-2: underestimated damage to nervous system**

Author name: Lingyan Zhou, Meng Zhang,
Jing Wang, Jing Gao

Declarations

Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated.

Conflict of Interest

A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any competing interests

The authors declare that they have no conflicts of interest.

Funding Source

All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated.

Please state any sources of funding for your research

No funding.

Signature (a scanned signature is acceptable, but each author must sign)

Lingyan Zhou

Meng Zhang

Jing Wang

Jing Gao

Print name